Sunmax Biotechnology Co

Sunmax Biotechnology Co EBITDA per Employee

The EBITDA per Employee of Sunmax Biotechnology Co (4728.TWO) as of Oct 21, 2026 is 26.98 M TWD. In the previous year, EBITDA per Employee was 25.05 M TWD — a change of 7.70% (higher).

EBITDA per Employee

26.98 MTWD

YoY

7.70%

Last updated:

EBITDA per Employee of Sunmax Biotechnology Co is 2025 26.98 M TWD. EBITDA per Employee of Sunmax Biotechnology Co was 2024 25.05 M TWD. It decreases by 7.70% higher compared to the previous year.

The Sunmax Biotechnology Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
1.73 M TWD
Jan 1, 2019
4.80 M TWD
Jan 1, 2020
9.36 M TWD
Jan 1, 2021
9.80 M TWD
Jan 1, 2022
21.02 M TWD
Jan 1, 2023
24.66 M TWD
Jan 1, 2024
25.05 M TWD
Jan 1, 2025
26.98 M TWD
The Sunmax Biotechnology Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
26.98 MTWD+7.70%
25.05 MTWD+1.59%
24.66 MTWD+17.33%
21.02 MTWD+114.45%
9.80 MTWD+4.67%
9.36 MTWD+95.16%
4.80 MTWD+177.69%
1.73 MTWD+381.67%
358,702.70TWD+328.54%
83,702.70TWD-106.46%
-1.30 MTWD-465.13%
355,027.03TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunmax Biotechnology Co Stock analysis

What does Sunmax Biotechnology Co do? SunMax Biotechnology Co., Ltd. generates revenue through the development, manufacturing, and commercialization of medical devices, biomedical materials, and bio surgical products. Its major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, and medical collagen application equipment. These products are sold to customers in the medical and beauty care industries across Taiwan, Mainland China, and other regions. The company's distribution focuses on these key markets, leveraging its product portfolio for healthcare and aesthetic applications. The firm's product line targets both medical and beauty care sectors, with collagen-based solutions serving as core offerings. Medical collagen application equipment supports clinical procedures, while collagen implants and hemostat products address surgical and wound care needs. The company's presence in Taiwan, Mainland China, and other regions enables it to serve diverse healthcare markets with standardized product offerings. SunMax Biotechnology's revenue streams are derived from the sale of collagen-based medical devices and equipment, with a focus on applications in surgery, wound care, and aesthetic treatments. By distributing its products through established channels in Taiwan, Mainland China, and other regions, the company capitalizes on demand for biocompatible materials in healthcare and beauty care industries. Sunmax Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunmax Biotechnology Co stock

EBITDA per Employee of Sunmax Biotechnology Co is 26.98 M TWD in 2025.

EBITDA per Employee of Sunmax Biotechnology Co changed from 25.05 M TWD to 26.98 M TWD, representing a 7.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Sunmax Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Sunmax Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Sunmax Biotechnology Co

All Key Metrics — Sunmax Biotechnology Co